List of Tables
Table 1. Acute Myeloid Leukemia Market Trends
Table 2. Acute Myeloid Leukemia Market Drivers & Opportunity
Table 3. Acute Myeloid Leukemia Market Challenges
Table 4. Acute Myeloid Leukemia Market Restraints
Table 5. Global Acute Myeloid Leukemia Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Acute Myeloid Leukemia Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Acute Myeloid Leukemia Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Acute Myeloid Leukemia Product Type
Table 9. Key Companies Time to Begin Mass Production of Acute Myeloid Leukemia
Table 10. Global Acute Myeloid Leukemia Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Acute Myeloid Leukemia Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Acute Myeloid Leukemia Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Acute Myeloid Leukemia Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Acute Myeloid Leukemia Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Acute Myeloid Leukemia Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Acute Myeloid Leukemia Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Acute Myeloid Leukemia Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Acute Myeloid Leukemia Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Acute Myeloid Leukemia Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Acute Myeloid Leukemia Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Acute Myeloid Leukemia Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Acute Myeloid Leukemia Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Acute Myeloid Leukemia Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Acute Myeloid Leukemia Sales Value by Region (2019-2024) & (%)
Table 27. Global Acute Myeloid Leukemia Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Acute Myeloid Leukemia Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Acute Myeloid Leukemia Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Acute Myeloid Leukemia Sales Value, (2025-2030) & (US$ Million)
Table 31. GSK Basic Information List
Table 32. GSK Description and Business Overview
Table 33. GSK Acute Myeloid Leukemia Products, Services and Solutions
Table 34. Revenue (US$ Million) in Acute Myeloid Leukemia Business of GSK (2019-2024)
Table 35. GSK Recent Developments
Table 36. Novartis Basic Information List
Table 37. Novartis Description and Business Overview
Table 38. Novartis Acute Myeloid Leukemia Products, Services and Solutions
Table 39. Revenue (US$ Million) in Acute Myeloid Leukemia Business of Novartis (2019-2024)
Table 40. Novartis Recent Developments
Table 41. Roche Basic Information List
Table 42. Roche Description and Business Overview
Table 43. Roche Acute Myeloid Leukemia Products, Services and Solutions
Table 44. Revenue (US$ Million) in Acute Myeloid Leukemia Business of Roche (2019-2024)
Table 45. Roche Recent Developments
Table 46. Bristol-Myers Squibb Basic Information List
Table 47. Bristol-Myers Squibb Description and Business Overview
Table 48. Bristol-Myers Squibb Acute Myeloid Leukemia Products, Services and Solutions
Table 49. Revenue (US$ Million) in Acute Myeloid Leukemia Business of Bristol-Myers Squibb (2019-2024)
Table 50. Bristol-Myers Squibb Recent Developments
Table 51. Celgene Basic Information List
Table 52. Celgene Description and Business Overview
Table 53. Celgene Acute Myeloid Leukemia Products, Services and Solutions
Table 54. Revenue (US$ Million) in Acute Myeloid Leukemia Business of Celgene (2019-2024)
Table 55. Celgene Recent Developments
Table 56. Clavis Pharma ASA Basic Information List
Table 57. Clavis Pharma ASA Description and Business Overview
Table 58. Clavis Pharma ASA Acute Myeloid Leukemia Products, Services and Solutions
Table 59. Revenue (US$ Million) in Acute Myeloid Leukemia Business of Clavis Pharma ASA (2019-2024)
Table 60. Clavis Pharma ASA Recent Developments
Table 61. Daiichi Sankyo Basic Information List
Table 62. Daiichi Sankyo Description and Business Overview
Table 63. Daiichi Sankyo Acute Myeloid Leukemia Products, Services and Solutions
Table 64. Revenue (US$ Million) in Acute Myeloid Leukemia Business of Daiichi Sankyo (2019-2024)
Table 65. Daiichi Sankyo Recent Developments
Table 66. Eisai Basic Information List
Table 67. Eisai Description and Business Overview
Table 68. Eisai Acute Myeloid Leukemia Products, Services and Solutions
Table 69. Revenue (US$ Million) in Acute Myeloid Leukemia Business of Eisai (2019-2024)
Table 70. Eisai Recent Developments
Table 71. Teva Basic Information List
Table 72. Teva Description and Business Overview
Table 73. Teva Acute Myeloid Leukemia Products, Services and Solutions
Table 74. Revenue (US$ Million) in Acute Myeloid Leukemia Business of Teva (2019-2024)
Table 75. Teva Recent Developments
Table 76. Sunesis Pharmaceuticals Basic Information List
Table 77. Sunesis Pharmaceuticals Description and Business Overview
Table 78. Sunesis Pharmaceuticals Acute Myeloid Leukemia Products, Services and Solutions
Table 79. Revenue (US$ Million) in Acute Myeloid Leukemia Business of Sunesis Pharmaceuticals (2019-2024)
Table 80. Sunesis Pharmaceuticals Recent Developments
Table 81. Key Raw Materials Lists
Table 82. Raw Materials Key Suppliers Lists
Table 83. Acute Myeloid Leukemia Downstream Customers
Table 84. Acute Myeloid Leukemia Distributors List
Table 85. Research Programs/Design for This Report
Table 86. Key Data Information from Secondary Sources
Table 87. Key Data Information from Primary Sources
Table 88. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Acute Myeloid Leukemia Product Picture
Figure 2. Global Acute Myeloid Leukemia Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Acute Myeloid Leukemia Sales Value (2019-2030) & (US$ Million)
Figure 4. Acute Myeloid Leukemia Report Years Considered
Figure 5. Global Acute Myeloid Leukemia Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Acute Myeloid Leukemia Revenue in 2023
Figure 7. Acute Myeloid Leukemia Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Chemotherapy Picture
Figure 9. Targeted Therapy Picture
Figure 10. Global Acute Myeloid Leukemia Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Acute Myeloid Leukemia Sales Value Market Share by Type, 2023 & 2030
Figure 12. Product Picture of Adults
Figure 13. Product Picture of Children
Figure 14. Global Acute Myeloid Leukemia Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Acute Myeloid Leukemia Sales Value Market Share by Application, 2023 & 2030
Figure 16. North America Acute Myeloid Leukemia Sales Value (2019-2030) & (US$ Million)
Figure 17. North America Acute Myeloid Leukemia Sales Value by Country (%), 2023 VS 2030
Figure 18. Europe Acute Myeloid Leukemia Sales Value (2019-2030) & (US$ Million)
Figure 19. Europe Acute Myeloid Leukemia Sales Value by Country (%), 2023 VS 2030
Figure 20. Asia Pacific Acute Myeloid Leukemia Sales Value (2019-2030) & (US$ Million)
Figure 21. Asia Pacific Acute Myeloid Leukemia Sales Value by Country (%), 2023 VS 2030
Figure 22. South America Acute Myeloid Leukemia Sales Value (2019-2030) & (US$ Million)
Figure 23. South America Acute Myeloid Leukemia Sales Value by Country (%), 2023 VS 2030
Figure 24. Middle East & Africa Acute Myeloid Leukemia Sales Value (2019-2030) & (US$ Million)
Figure 25. Middle East & Africa Acute Myeloid Leukemia Sales Value by Country (%), 2023 VS 2030
Figure 26. Key Countries/Regions Acute Myeloid Leukemia Sales Value (%), (2019-2030)
Figure 27. United States Acute Myeloid Leukemia Sales Value, (2019-2030) & (US$ Million)
Figure 28. United States Acute Myeloid Leukemia Sales Value by Type (%), 2023 VS 2030
Figure 29. United States Acute Myeloid Leukemia Sales Value by Application (%), 2023 VS 2030
Figure 30. Europe Acute Myeloid Leukemia Sales Value, (2019-2030) & (US$ Million)
Figure 31. Europe Acute Myeloid Leukemia Sales Value by Type (%), 2023 VS 2030
Figure 32. Europe Acute Myeloid Leukemia Sales Value by Application (%), 2023 VS 2030
Figure 33. China Acute Myeloid Leukemia Sales Value, (2019-2030) & (US$ Million)
Figure 34. China Acute Myeloid Leukemia Sales Value by Type (%), 2023 VS 2030
Figure 35. China Acute Myeloid Leukemia Sales Value by Application (%), 2023 VS 2030
Figure 36. Japan Acute Myeloid Leukemia Sales Value, (2019-2030) & (US$ Million)
Figure 37. Japan Acute Myeloid Leukemia Sales Value by Type (%), 2023 VS 2030
Figure 38. Japan Acute Myeloid Leukemia Sales Value by Application (%), 2023 VS 2030
Figure 39. South Korea Acute Myeloid Leukemia Sales Value, (2019-2030) & (US$ Million)
Figure 40. South Korea Acute Myeloid Leukemia Sales Value by Type (%), 2023 VS 2030
Figure 41. South Korea Acute Myeloid Leukemia Sales Value by Application (%), 2023 VS 2030
Figure 42. Southeast Asia Acute Myeloid Leukemia Sales Value, (2019-2030) & (US$ Million)
Figure 43. Southeast Asia Acute Myeloid Leukemia Sales Value by Type (%), 2023 VS 2030
Figure 44. Southeast Asia Acute Myeloid Leukemia Sales Value by Application (%), 2023 VS 2030
Figure 45. India Acute Myeloid Leukemia Sales Value, (2019-2030) & (US$ Million)
Figure 46. India Acute Myeloid Leukemia Sales Value by Type (%), 2023 VS 2030
Figure 47. India Acute Myeloid Leukemia Sales Value by Application (%), 2023 VS 2030
Figure 48. Acute Myeloid Leukemia Industrial Chain
Figure 49. Acute Myeloid Leukemia Manufacturing Cost Structure
Figure 50. Channels of Distribution (Direct Sales, and Distribution)
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
